On the other hand, our findings that circulating S1P levels were lower in Her2-enriched and triple-negative breast cancer patients are consistent with previous publications identifying that breast tumor S1P levels were lower in those patients with aggressive tumors [14]. Here, ERBB2 is linked to triple-negative breast carcinoma.